

#### Name of the issue: Krishna Institute of Medical Sciences Limited

Type of issue (IPO/ FPO)

IPO

2 Issue size (Rs. in crore)

2,144.00

3 Grade of issue alongwith name of the rating agency

Name Grade

Not Applicable

4 Subscription Level (Number of times) (1)

Overall 3.9

Source: Basis Minutes

(1) Before technical rejections

#### 5 QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) On Allotment	26.30%
(ii) at the end of the 1st Quarter immediately af	27.85%
of the issue (June 30, 2021)	
(iii) at the end of 1st FY (March 31, 2022)	29.93%
(iv) at the end of 2nd FY (March 31, 2023)	19.40%
(v) at the end of 3rd FY (March 31, 2024) <sup>(1)</sup>	Not Available

<sup>(1)</sup> Will be updated in due course

#### 6 Financials of the issuer

(Consolidated Rs. in crore)

		\ -	,
Parameters	31-Mar-22	31-Mar-23	31-Mar-24
Net Sales/ Income from operations	1651	2198	Not Available
Net Profit after Minority Interest	344	366	Not Available
Equity Capital	80	80	Not Available
Reserves excluding revaluation reserves	1307	1589	Not Available

Note: Financials for the year ended March 31, 2024 shall be updated in due course



## 7 Trading status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	
(i) at the one of feth i (Maren or, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024) (1)	Not Available
(1) will be updated in due course	

## 8 Change, if any, in directors of issuer from the disclosures in the offer document

Particulars	Name of Director		Appointed / Resigned
During year ended March 31, 2022		-	
During year ended March 31, 2023	Sandeep Naik	Resig	gned
	Y Prameela Naik	Appo	inted
During year ended March 31, 2024 (1)	Not Available		
(d) Information about he constated in due course	•	·	

<sup>(1)</sup> Information shall be updated in due course

# Status of implementation of project/ commencement of commercial production

Particulars	Remarks
(i) as disclosed in the offer document	
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	

## 10 Status of utilization of issue proceeds

as disclosed		

Total estimated amount / expenditure	Amount to be deployed from the Net Proceeds in Fiscal 2022		
1,500.00	1,500.00		
500.00	500.00		
2,000.00	2,000.00		
	1,500.00 500.00		



(ii) Actual utilization2,000.00(iii) Reasons for deviation, if anyNA

## 11 Comments of monitoring agency, if applicable

Nil

#### 12 Price-related data

Designated SE BSE Issue Price (Rs.) 825 Listing Date 28-Jun-21

Price parameters	At close of listing day June 28, 2021	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the er	nd of March 31	, 2022
				Closing price	High during	Low during
				during FY	FY	FY
Market Price	995.90	1,200.20	1,223.00	1,379.95	1,532.15	938.05
Sensex	52,735.60	52,443.70	59,667.60	58,568.51	62,245.43	47,204.50
Sectoral Index		Not comparable to	any of the available se	ectoral indices		
Price parameters	As at the end of March 31, 2023 As at the end of March 31, 2024 <sup>(1)</sup> Closing price High during Low during				2024 <sup>(1)</sup> Low during	
	Closing price during FY	High during FY	Low during FY	during FY	FY	FY
Market Price	1,401.45	1,668.40	1,113.25	Not Available	Not Available	Not
			·			Available
Nifty	17,359.75	18,887.60	15,183.40	Not Available	Not Available	Not
						Available

Source: Stock Exchange data. Where the 30th day / 90th day / March 31 of a particular year falls on a holiday, the immediately following trading day has been considered (1) will be updated in due course



## 13 Basis for Issue Price and Comparison with Peer Group & Industry Average

ccounting ratio	Name of company	the offer	Ane end of 1st arch 31, 2022	t the end of 2nd FY March 31, 2023	At the end of 3rd FY March 31, 2024
	Issuer: Consolidated	26.90	35.04	42.03	
	Peer Group:				
	Apollo Hospitals	32.7	73.42	56.97	
Basic and Diluted EPS	Fortis Healthcare	-1.5	7.35	7.8	
	Narayana Hrudalaya	-0.7	16.85	13.08	
	Max Healthcare	-1.6	6.25	7.16	
	Industry Avg	7.23	25.97	21.25	
	Issuer: Consolidated	31.2	39.38	33.46	
	Peer Group:				
	Apollo Hospitals	101.4	61.51	75.64	
P/E	Fortis Healthcare	NA	39.46	33.33	
	Narayana Hrudalaya	NA	44.27	59.18	
	Max Healthcare	NA	55.52	61.59	
	Industry Avg	101.4	50.19	57.44	
	Issuer:Consolidated	23.30	24.80	21.93	
	Peer Group:				
	Apollo Hospitals	12.9	19.63	13.65	
RoNW%	Fortis Healthcare	1.4	11.27	8.74	
	Narayana Hrudalaya	10.5	22.97	18.09	
	Max Healthcare	9.7	9.63	9.86	
	Industry Avg:	8.63	15.88	12.59	
	Issuer:Consolidated	115.4	173.38	208.63	
	Peer Group:				
	Apollo Hospitals	240	393.12	431	
NAV per share based on balance sheet	Fortis Healthcare	89	92.83	95.93	
	Narayana Hrudalaya	54.9	73.00	104.3	
	Max Healthcare	57.3	64.79	64.69	
	Industry Avg:	110.30	155.94	173.98	

Source: Prospectus

# 14 Any other material information

For updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com